drugset / Trial / NCT02795156
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
Phase 2
Completed
100 enrolled
SCRI Development Innovations, LLC
Bayer · collabBoehringer Ingelheim · collabExelixis · collabFoundation Medicine · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
With the increased availability of next-generation sequencing, oncologists are starting to incorporate genomic profiling into routine care of cancer patients. If a genomic alteration is identified during profiling, it could help guide the choice of therapy and improve treatment outcomes. This study will examine the anti-tumor activity of selected commercially available molecularly matched targeted therapies in patients who have failed first-line treatment for one of the following tumor types: non-small cell lung cancers; urothelial cancer; non-colon gastrointestinal cancers, and upper aerodigestive tract cancer.
Timeline
- Start
- 2016-09-28
- Primary completion
- 2022-08-17
- Completion
- 2022-08-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Afatinib | Small molecule | 40 mg | Oral |
| Subject | Cabozantinib | Small molecule | 60 mg | Oral |
| Subject | Regorafenib | Small molecule | 160 mg | Oral |